Cargando…

Retina stem cells, hopes and obstacles

Retinal degeneration is a major contributor to visual dysfunction worldwide. Although it comprises several eye diseases, loss of retinal pigment epithelial (RPE) and photoreceptor cells are the major contributors to their pathogenesis. Early therapies included diverse treatments, such as provision o...

Descripción completa

Detalles Bibliográficos
Autores principales: German, Olga L, Vallese-Maurizi, Harmonie, Soto, Tamara B, Rotstein, Nora P, Politi, Luis Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567457/
https://www.ncbi.nlm.nih.gov/pubmed/34786153
http://dx.doi.org/10.4252/wjsc.v13.i10.1446
_version_ 1784594237088595968
author German, Olga L
Vallese-Maurizi, Harmonie
Soto, Tamara B
Rotstein, Nora P
Politi, Luis Enrique
author_facet German, Olga L
Vallese-Maurizi, Harmonie
Soto, Tamara B
Rotstein, Nora P
Politi, Luis Enrique
author_sort German, Olga L
collection PubMed
description Retinal degeneration is a major contributor to visual dysfunction worldwide. Although it comprises several eye diseases, loss of retinal pigment epithelial (RPE) and photoreceptor cells are the major contributors to their pathogenesis. Early therapies included diverse treatments, such as provision of anti-vascular endothelial growth factor and many survival and trophic factors that, in some cases, slow down the progression of the degeneration, but do not effectively prevent it. The finding of stem cells (SC) in the eye has led to the proposal of cell replacement strategies for retina degeneration. Therapies using different types of SC, such as retinal progenitor cells (RPCs), embryonic SC, pluripotent SCs (PSCs), induced PSCs (iPSCs), and mesenchymal stromal cells, capable of self-renewal and of differentiating into multiple cell types, have gained ample support. Numerous preclinical studies have assessed transplantation of SC in animal models, with encouraging results. The aim of this work is to revise the different preclinical and clinical approaches, analyzing the SC type used, their efficacy, safety, cell attachment and integration, absence of tumor formation and immunorejection, in order to establish which were the most relevant and successful. In addition, we examine the questions and concerns still open in the field. The data demonstrate the existence of two main approaches, aimed at replacing either RPE cells or photoreceptors. Emerging evidence suggests that RPCs and iPSC are the best candidates, presenting no ethical concerns and a low risk of immunorejection. Clinical trials have already supported the safety and efficacy of SC treatments. Serious concerns are pending, such as the risk of tumor formation, lack of attachment or integration of transplanted cells into host retinas, immunorejection, cell death, and also ethical. However, the amazing progress in the field in the last few years makes it possible to envisage safe and effective treatments to restore vision loss in a near future.
format Online
Article
Text
id pubmed-8567457
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85674572021-11-15 Retina stem cells, hopes and obstacles German, Olga L Vallese-Maurizi, Harmonie Soto, Tamara B Rotstein, Nora P Politi, Luis Enrique World J Stem Cells Review Retinal degeneration is a major contributor to visual dysfunction worldwide. Although it comprises several eye diseases, loss of retinal pigment epithelial (RPE) and photoreceptor cells are the major contributors to their pathogenesis. Early therapies included diverse treatments, such as provision of anti-vascular endothelial growth factor and many survival and trophic factors that, in some cases, slow down the progression of the degeneration, but do not effectively prevent it. The finding of stem cells (SC) in the eye has led to the proposal of cell replacement strategies for retina degeneration. Therapies using different types of SC, such as retinal progenitor cells (RPCs), embryonic SC, pluripotent SCs (PSCs), induced PSCs (iPSCs), and mesenchymal stromal cells, capable of self-renewal and of differentiating into multiple cell types, have gained ample support. Numerous preclinical studies have assessed transplantation of SC in animal models, with encouraging results. The aim of this work is to revise the different preclinical and clinical approaches, analyzing the SC type used, their efficacy, safety, cell attachment and integration, absence of tumor formation and immunorejection, in order to establish which were the most relevant and successful. In addition, we examine the questions and concerns still open in the field. The data demonstrate the existence of two main approaches, aimed at replacing either RPE cells or photoreceptors. Emerging evidence suggests that RPCs and iPSC are the best candidates, presenting no ethical concerns and a low risk of immunorejection. Clinical trials have already supported the safety and efficacy of SC treatments. Serious concerns are pending, such as the risk of tumor formation, lack of attachment or integration of transplanted cells into host retinas, immunorejection, cell death, and also ethical. However, the amazing progress in the field in the last few years makes it possible to envisage safe and effective treatments to restore vision loss in a near future. Baishideng Publishing Group Inc 2021-10-26 2021-10-26 /pmc/articles/PMC8567457/ /pubmed/34786153 http://dx.doi.org/10.4252/wjsc.v13.i10.1446 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Review
German, Olga L
Vallese-Maurizi, Harmonie
Soto, Tamara B
Rotstein, Nora P
Politi, Luis Enrique
Retina stem cells, hopes and obstacles
title Retina stem cells, hopes and obstacles
title_full Retina stem cells, hopes and obstacles
title_fullStr Retina stem cells, hopes and obstacles
title_full_unstemmed Retina stem cells, hopes and obstacles
title_short Retina stem cells, hopes and obstacles
title_sort retina stem cells, hopes and obstacles
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567457/
https://www.ncbi.nlm.nih.gov/pubmed/34786153
http://dx.doi.org/10.4252/wjsc.v13.i10.1446
work_keys_str_mv AT germanolgal retinastemcellshopesandobstacles
AT vallesemauriziharmonie retinastemcellshopesandobstacles
AT sototamarab retinastemcellshopesandobstacles
AT rotsteinnorap retinastemcellshopesandobstacles
AT politiluisenrique retinastemcellshopesandobstacles